title: Effects of immunoglobulin to prevent coronary allograft vasculopathy in heart transplantation.
abstract: BACKGROUND
  Although 100,000 cardiac transplants have been performed, coronary allograft vasculopathy (CAV), which is a phenomenon of chronic rejection, is still a serious problem.
  
  
  METHODS
  Several adhesion molecules, cytokines, and chemokines play a critical role in the process. Recent investigations have proved some promising methodologies for preventing or treating rejection. Although immunoglobulins are known to be an effective treatment in many diseases, their effect on cardiac transplantation or CAV is to be elucidated.
  
  
  CONCLUSIONS
  In this review article, we described some promising methodologies that use immunoglobulins to prevent CAV. Immunoglobulins may be used to prevent CAV.
authors: University of Tokyo, Graduate School of Medicine, Department of Advanced Clinical Science and Therapeutics, 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan. junichisuzuki-circ@umin.ac.jp
authors: Jun-ichi
authors: J
authors: Suzuki
authors: Masahito
authors: M
authors: Ogawa
authors: Yasunobu
authors: Y
authors: Hirata
authors: Ryozo
authors: R
authors: Nagai
authors: Mitsuaki
authors: M
authors: Isobe
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D016027:Heart Transplantation; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D014184:Transplantation, Homologous
chemical_list: D007136:Immunoglobulins